This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Sep;12(9):827-8.

doi: 10.1016/S1470-2045(11)70236-4. Epub 2011 Aug 19.

PARP inhibitors in cancer: moving beyond BRCA

Melinda L Telli¹

Affiliations

PMID: 21862406
DOI: 10.1016/S1470-2045(11)70236-4

Comment

PARP inhibitors in cancer: moving beyond BRCA

Melinda L Telli. Lancet Oncol. 2011 Sep.

. 2011 Sep;12(9):827-8.

doi: 10.1016/S1470-2045(11)70236-4. Epub 2011 Aug 19.

Author

Melinda L Telli¹

Affiliation

¹ Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA. mtelli@stanford.edu

PMID: 21862406
DOI: 10.1016/S1470-2045(11)70236-4

No abstract available

PubMed Disclaimer

Comment on

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Gelmon KA, et al. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.

Similar articles

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Gelmon KA, et al. Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19. Lancet Oncol. 2011. PMID: 21862407 Clinical Trial.
[Research progresses of the PARP inhibitors for the treatment of cancer].
He YJ, Liu RH, Ning CQ, Yu NF. He YJ, et al. Yao Xue Xue Bao. 2013 May;48(5):655-60. Yao Xue Xue Bao. 2013. PMID: 23888686 Review. Chinese.
PARP inhibitors in BRCA mutation-associated ovarian cancer.
Clamp A, Jayson G. Clamp A, et al. Lancet Oncol. 2015 Jan;16(1):10-2. doi: 10.1016/S1470-2045(14)71172-6. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481790 No abstract available.
The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
Nirsimloo R, Gourley C. Nirsimloo R, et al. Expert Rev Anticancer Ther. 2016 Jun;16(6):597-603. doi: 10.1080/14737140.2016.1182429. Expert Rev Anticancer Ther. 2016. PMID: 27115428 Review.
Olaparib for the treatment of ovarian cancer.
Bornstein E, Jimeno A. Bornstein E, et al. Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714. Drugs Today (Barc). 2016. PMID: 26937492 Review.

See all similar articles

Cited by

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.
Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Rosellini M, et al. Nat Rev Urol. 2023 Mar;20(3):133-157. doi: 10.1038/s41585-022-00676-0. Epub 2022 Nov 21. Nat Rev Urol. 2023. PMID: 36414800 Review.
ARTD2 activity is stimulated by RNA.
Léger K, Bär D, Savić N, Santoro R, Hottiger MO. Léger K, et al. Nucleic Acids Res. 2014 Apr;42(8):5072-82. doi: 10.1093/nar/gku131. Epub 2014 Feb 8. Nucleic Acids Res. 2014. PMID: 24510188 Free PMC article.
Major clinical research advances in gynecologic cancer in 2011.
Suh DH, Kim K, Kim JW. Suh DH, et al. J Gynecol Oncol. 2012 Jan;23(1):53-64. doi: 10.3802/jgo.2012.23.1.53. Epub 2012 Jan 9. J Gynecol Oncol. 2012. PMID: 22355468 Free PMC article.
Efforts to make and apply humanized yeast.
Laurent JM, Young JH, Kachroo AH, Marcotte EM. Laurent JM, et al. Brief Funct Genomics. 2016 Mar;15(2):155-63. doi: 10.1093/bfgp/elv041. Epub 2015 Oct 13. Brief Funct Genomics. 2016. PMID: 26462863 Free PMC article. Review.
Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases.
Rosenthal F, Feijs KL, Frugier E, Bonalli M, Forst AH, Imhof R, Winkler HC, Fischer D, Caflisch A, Hassa PO, Lüscher B, Hottiger MO. Rosenthal F, et al. Nat Struct Mol Biol. 2013 Apr;20(4):502-7. doi: 10.1038/nsmb.2521. Epub 2013 Mar 10. Nat Struct Mol Biol. 2013. PMID: 23474714

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information